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Background: Tumor necrosis factor, which exists both as a soluble (solTNF) and a
transmembrane (tmTNF) protein, plays an important role in post-stroke inflammation.
The objective of the present study was to test the effect of topical versus
intracerebroventricular administration of XPro1595 (a solTNF inhibitor) and etanercept
(a solTNF and tmTNF inhibitor) compared to saline on output measures such as infarct
volume and post-stroke inflammation in mice.
Methods: Adult male C57BL/6 mice were treated topically (2.5 mg/ml/1µl/h for 3
consecutive days) or intracerebroventricularly (1.25 mg/kg/0.5 ml, once) with saline,
XPro1595, or etanercept immediately after permanent middle cerebral artery occlusion
(pMCAO). Mice were allowed to survive 1 or 3 days. Infarct volume, microglial and
leukocyte profiles, and inflammatory markers were evaluated.
Results: We found that topical, and not intracerebroventricular, administration of
XPro1595 reduced infarct volume at both 1 and 3 days after pMCAO. Etanercept
showed no effect. We observed no changes in microglial or leukocyte populations.
XPro1595 increased gene expression of P2ry12 at 1 day and Trem2 at 1 and 3 days,
while decreasing Cx3cr1 expression at 1 and 3 days after pMCAO, suggesting a change
in microglial activation toward a phagocytic phenotype.
Conclusion: Our data demonstrate that topical administration of XPro1595 for 3
consecutive days decreases infarct volumes after ischemic stroke, while modifying
microglial activation and the inflammatory response post-stroke. This suggests that
inhibitors of solTNF hold great promise for future neuroprotective treatment in
ischemic stroke.
Keywords: ischemic stroke, behavior, cytokines, microglial activation, neuroprotection
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INTRODUCTION
Inflammatory events after ischemic stroke contribute to
secondary injury mechanisms that can expand tissue injury
and are thus targets of new treatment options (Lambertsen
et al., 2018). Tumor necrosis factor (TNF) is a multifunctional,
proinflammatory cytokine that participates in all phases of
ischemic stroke, from development to repair and long-term
inflammatory effects (reviewed in Hallenbeck, 2002). It exists
both as a transmembrane (tmTNF) and a soluble (solTNF)
protein, the latter released via proteolytic cleavage by TNFα
converting enzyme (TACE, also called ADAM17) (Black et al.,
1997). TNF mediates its effects via TNF receptor 1 (TNFR1,
p55TNFR) and 2 (TNFR2, p75TNFR); solTNF primarily
mediates acute and chronic inflammation, while tmTNF has
been shown to support innate immune function and promote
neuronal survival and axonal remyelination, synaptic function,
and neurotransmission (Ruuls et al., 2001; Alexopoulou et al.,
2006; Brambilla et al., 2011; Barnum et al., 2014; Cavanagh
et al., 2016). In ischemic stroke, TNF plays an important role in
infarct development (Lambertsen et al., 2018). In support of this,
conventional (Lambertsen et al., 2009) and conditional myeloid
(Clausen et al., 2016a) deletion of TNF resulted in increased
infarct volumes in mice subjected to permanent middle cerebral
artery occlusion (pMCAO). Interestingly, genetic ablation of
solTNF using tmTNF1/1 mice resulted in decreased infarct
volumes after pMCAO (Madsen et al., 2016), suggesting that
inhibition of solTNF, but preservation of tmTNF, is required for
neuroprotection in ischemic stroke.
Current FDA- and EMA-approved TNF inhibitors are used
for treating chronic autoimmune inflammatory diseases such as
rheumatoid arthritis, inflammatory bowel disease, and psoriasis
(Lis et al., 2014), where they also relieve potential symptoms of
depression (Tyring et al., 2006). The dimeric Fc-fusion protein
etanercept targets both tmTNF and solTNF. Being a large
(150 kDa) protein, it is not able to cross the blood-brain barrier.
When administered perispinally, however, etanercept improved
neurological outcome in patients with chronic stroke, traumatic
brain injury and Alzheimer’s disease (Griffin, 2008; Tobinick,
2011; Tobinick et al., 2012; and reviewed in Lambertsen et al.,
2018). The downside of drugs like etanercept is that inhibition
Abbreviations: 3-MPST, 3-mercaptopyruvate sulfurtransferase; Arg1, arginase 1;
CCL2, C-C motif chemokine ligand 2; CV, coefficient of variation; CXCL1, C-X-
C motif chemokine ligand 1; CXCL10, C-X-C motif chemokine ligand 10; Cx3cr1,
C-X3-C motif chemokine receptor 1; FBS, fetal bovine serum; FDR, false discovery
rate; FMO, fluorescence minus one; HBSS, Hanks’ Balanced Salt Solution; HGTD-
P, human growth and transformation-dependent protein; HPGDS, hematopoetic
prostaglandin D synthase; HPRT1, hypoxanthine phosphoribosyltransferase 1;
i.c.v., intracerebroventricular; IL-1β, interleukin-1β, INOS, inducible nitric oxide
synthase; LPS, lipopolysaccharide; MCA, middle cerebral artery; MECP, methyl-
CgP-binding protein 2; MFI, mean fluorescent intensity; MPO, myeloperoxidase;
PBS, phosphate buffered saline; pMCAO, permanent middle cerebral artery
occlusion; P2ry12, P2Y purinoceptor 12; PYCARD, apoptosis-associated speck-
like protein containing CARD; RIN, RNA integrity factor; RT-PCR, reverse
transcriptase-polymerase chain reaction; s.c., subcutaneously; solTNF, soluble
tumor necrosis factor; SSC, side scatter; TACE, tumor necrosis factor alpha
converting enzyme; tmTNF, transmembrane tumor necrosis factor; TNF, tumor
necrosis factor; TNFR1, tumor necrosis factor 1; TNFR2, tumor necrosis factor
2; Trem2, triggering receptor expressed on myeloid cells-2; UPLC-MS/MS,
ultra-performance liquid chromatography-tandem mass spectrometry.
of both solTNF and tmTNF can provoke demyelination and
induce neuropathies, infections, sepsis, congestive heart failure
and lupus, emphasizing the importance of leaving tmTNF
available to preserve adequate function of the innate immune
system (Scheinfeld, 2004). XPro1595 is a dominant-negative
inhibitor of solTNF (Steed et al., 2003). In animal models
of multiple sclerosis, XPro1595 promotes axonal preservation
and remyelination (Brambilla et al., 2011); in Parkinson’s
disease XPro1595 reduces neuronal loss (McCoy et al., 2006;
Barnum et al., 2014); in Alzheimer’s disease it decreases beta-
amyloid plaques and promotes synaptic function (Cavanagh
et al., 2016; MacPherson et al., 2017); and in spinal cord
injury it decreases lesion volume (Novrup et al., 2014). We
have previously shown that using etanercept and XPro1595 for
systemic inhibition of TNF improved functional outcome and
affected the inflammatory response after pMCAO in mice, but
with no effect on infarct volume (Clausen et al., 2014). The altered
inflammatory response after systemic administration of TNF
inhibitors was likely a result of peripheral immunomodulation
that decreased the granulocyte infiltration to the ischemic lesion,
which was earlier shown to be neuroprotective (Soriano et al.,
1999; Clausen et al., 2014). Peripheral treatment likely also
changed microglial activation (Clausen et al., 2014). In light of
these studies and our earlier studies demonstrating that topical
(and not systemic) administration of XPro1595 decreased lesion
size following moderate spinal cord injury (Novrup et al., 2014),
we hypothesized that topical and/or intracerebroventricular
(i.c.v.) delivery of XPro1595 would reduce lesion size, ameliorate
brain inflammation, and improve functional outcome after focal
cerebral ischemia in mice.
MATERIALS AND METHODS
Animals
Adult male C57BL/6 mice (aged 7–8 weeks) were purchased from
Taconic Ltd. (Ry, Denmark) and transferred to the Biomedical
Laboratory at the University of Southern Denmark, Odense,
Denmark. tmTNF1/1 (Ruuls et al., 2001) breeding couples were
kindly donated by Dr. Tacchini-Cottier, University of Lausanne,
Switzerland and a breeding colony was established at the
Biomedical Laboratory at the University of Southern Denmark.
Animals were housed under diurnal lighting conditions, and
food and water were available ad libitum. Mice were allowed
to acclimatize for at least 1 week before behavioral testing.
All animal experiments were approved by the Danish Animal
Inspectorate under the Ministry of Food and Agriculture (J. No.
2013-15-2934-00924).
Permanent Middle Cerebral Artery
Occlusion
Permanent occlusion of the distal part of the middle cerebral
artery was performed by electrocoagulation under Hypnorm-
Dormicum anesthesia (fentanyl citrate (0.315 mg/ml, Jansen-
Cilag), fluanisone (10 mg/ml, Jansen-Cilag, Birkerød, Denmark),
and midazolam (5 mg/ml, Hoffmann-La Roche, Hvidovre,
Denmark) as routinely done in our laboratory (Lambertsen et al.,
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2001, 2009; Clausen et al., 2014, 2016b). Post-operatively, mice
were injected with 0.9% physiological saline subcutaneously (s.c.)
and placed in a 28◦C heating cabinet for 24 h. Mice with 3 days
survival were returned to the conventional animal facility after
24 h. Buprenorphine hydrochloride (0.001 mg/20 g Temgesic,
Schering-Plough, Ballerup, Denmark) was administered three
times at 8 h intervals starting immediately prior to surgery.
Sham mice were subjected to similar surgery but without
electrocoagulation of the middle cerebral artery (MCA).
Pharmacological Treatment
Saline, XPro1595 (Xencor Inc., Monrovia, CA, United States),
or etanercept (Enbrel, Amgen-Wyeth, Thousand Oak, CA,
United States) was administered topically using mini-osmotic
pumps (Alzet, 1003D, Durect Corporation, Cupertino, CA,
United States) implanted 30 min after pMCAO. XPro1595 and
etanercept were diluted in saline for the final concentration. The
pumps were placed in such a way that the delivering end of
the catheter was on top of the infarct core. The catheter was
sutured to the musculature, and the suture and placement of it
were secured using Vetbond (3M Animal Care Products, St. Paul,
MN, United States). The pumps were set to deliver either saline
(0.9% physiological NaCl) with a flow of 1 µl/h, XPro1595 or
etanercept with a flow of 2.5 mg/ml/1µl/h for 3 consecutive days,
as previously described (Novrup et al., 2014).
In addition, intracerebroventricular (i.c.v.) injection of saline,
XPro1595, or etanercept was performed 30 min after pMCAO.
For i.c.v. delivery, animals were fixed in a stereotactic frame
(David Kopf Instruments, United States) immediately after
pMCAO, and anesthesia was maintained with isoflurane (2%
isoflurane in O2). One single i.c.v. injection (0.5 µl) of either
saline, XPro1595 (1.25 mg/kg), or etanercept (1.25 mg/kg)
was administered using a 2 µl Hamilton micro-syringe. The
injection was made in the left lateral ventricle using the following
coordinates with reference to bregma: anterior -0.2 mm; lateral
0.9 mm; ventral 2.5 mm; tooth-bar -1.0 mm. After injection,
the syringe was left in place for a further 5 min before being
slowly retracted.
Group Size and Study Design
Groups of mice for infarct volumetric, functional, and
inflammatory analyses consisted of mice treated topically
for 1 day (n = 7–11/group) or for 3 days (n = 20/group) or
mice treated i.c.v. for 1 day (n = 6–7/group) or for 3 days
(n = 20/group) after pMCAO. Animals were excluded from
the study if the infarct volume was less than 3 mm3 due to
lack of successful occlusion of the MCA. Animals with MCA
bleedings were excluded due to hematoma formation. A total
of 29 mice subjected to pMCAO were excluded due to lack of
infarct or bleedings.
To evaluate microglial and leukocyte profiles, a group of sham-
treated mice were allowed to survive 3 days (n = 5/group).
Mice allowed to survive for 1 day (n = 5–6/group) or 3
days (n = 5/group) after pMCAO were included for flow
cytometric studies.
Mortality was 9% and independent of treatment. In total,
in the day one groups, 2 mice treated topically with saline, 1
mouse treated topically with XPro1595, 1 mouse treated i.c.v.
with XPro1595, and 1 mouse treated i.c.v. with etanercept died.
In the day 3 groups, 1 mouse with 3 days survival treated topically
with saline, 2 mice treated topically with XPro1595, and 1 mouse
treated topically with etanercept, 2 mice treated i.c.v. with saline,
1 mouse treated i.c.v. with XPro1595, and 3 mice treated i.c.v.
with etanercept died.
Behavioral Tests
Functional outcome was evaluated using the Hargreaves test (2
days after surgery) and a grip strength test (3 days after surgery).
Prior to behavioral testing, mice were allowed to acclimatize in
the behavior room. Neuromuscular testing of mice with mini-
osmotic pumps was not possible as the pumps were placed
in subcutaneous pockets on the lateral back of the mice and
affected the animals’ balance. Behavioral testing was therefore
only performed with i.c.v. treated mice.
Thermal Nociception Assay
Thermal hyperalgesia was evaluated using the Hargreaves
nociception assay (Hargreaves et al., 1988). The plantar test
(37370, Ugo Basile, Comerio VA, Italy) was used to measure the
withdrawal latencies after predisposing the hind paws to heat
(Clausen et al., 2016b). Five measurements were registered for
each hind paw prior to and 2 days after pMCAO; the lowest and
highest values were excluded, and the mean was calculated. Data
are presented as symmetry between contra- and ipsilateral hind
paws prior to and after surgery. The mice were allowed to recover
for 15 min between trials. Mice were excluded if they did not
complete all the trials. In total, four animals were excluded.
Grip Strength
Grip strength was measured 1 day prior to and 3 days
after surgery using a grip strength meter (BIO-GT-3, BIOSEB,
Vitrolles, France). We measured the peak force generated when
the mouse loosened its grip when being gently pulled horizontally
backwards. We tested both the front right (R) and the front left
(L) paw as well as the total grip strength. The peak force (g)
of five trials was recorded, and the highest score was registered.
Results are presented as delta (1) grip strength in grams (g),
representing the difference in grip strength prior to and after
pMCAO (Lambertsen et al., 2009; Clausen et al., 2014). Mice were
excluded if they could not complete the trials with both paws
separately and together. A total of four mice were excluded.
Tissue Processing
Fresh Frozen Tissue
Animals were sacrificed by cervical dislocation 1 or 3 days after
induction of ischemia. Brains were dissected, frozen in CO2 snow,
and stored at−80◦C until further processing. Brains were cut into
six parallel series of 30 µm thick sections as previously described
(Clausen et al., 2014).
Flow Cytometric Tissue
Mice treated topically with saline, XPro1595, or etanercept were
sacrificed 1 or 3 days after pMCAO or 3 days after sham
surgery. All mice were given an overdose of pentobarbital
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(200 mg/ml) containing lidocaine hydrochloride (20 mg/ml)
(Glostrup Apotek, Glostrup, Denmark) and perfused through
the left ventricle with phosphate buffered saline (PBS, pH 7.4).
Ipsilateral and contralateral cortices were dissected and placed
in Hanks’ balanced salt solution (HBSS) containing 10% fetal
bovine serum (FBS). Lymph nodes were collected for positive
detection of T cells. A pool of cells collected from ipsilateral
cortices was used for fluorescence minus one (FMO), and isotype
controls and a contralateral pool with cells from lymph nodes
for compensation. Live/dead cell staining was performed using
eBioscience Fixable Viability Dye eFluor 506 (Thermo Fisher
Scientific, Roskilde, Denmark).
The tissue was mechanically dissociated using 70 µm cell
strainers (BD Biosciences) as previously described (Madsen
et al., 2016). Samples were washed with FACS buffer containing
HBSS, 2% FBS, and 0.1% sodium azide, fixed with BD
Cytofix/Cytoperm (BD Biosciences) and blocked for non-specific
binding using 50 µg/ml Syrian Hamster Gamma Globulin
(Trichem) and Mouse BD Fc Block (BD Biosciences) diluted in
FACS buffer. For detection of microglia and leukocytes, cells were
incubated with CD45-PerCP-Cy5.5 (clone 30-F11) and CD11b-
PE (clone M7/70).
For separation of macrophages and granulocytes, the
following antibodies were used: Ly6C-PE-Cy7 (clone AL21)
and Ly6G-BV421 (clone 1A8). T cells were detected with
CD3-APC (clone 145-2C11). Respective isotype controls
were: IgG2b-PerCP-Cy5.5 (clone A95-1), IgG2b-PE (clone
A95-1), IgM-PE-Cy7 (clone R4-22), IgG2a-BV421 (clone
R35-95), and IgG1κ-APC (clone A19-3). All antibodies were
from BD Biosciences. Flow cytometry was performed as
previously described using FACSVerse (BD Biosciences)
and analyzed by FACSuite software (Clausen et al.,
2014). Positive staining for CD45dimCD11b+ microglia,
CD45highCD11b+LY6C+Ly6G− macrophages, CD45+CD3+
T cells, and CD45highCD11b+Ly6C+Ly6G+ granulocytes
was determined based on FMO controls and intensity of the
respective isotype control as previously described (Clausen
et al., 2016a; Madsen et al., 2016). A total of 1,000,000 events
were collected using side scatter (SSC). The mean fluorescence
intensity (MFI) was calculated as the geometric mean of
each population.
Infarct Volumetric and Rostrocaudal Distribution
Analysis
Every sixth section was stained with Toluidine blue, and
infarct volume was estimated based on Cavalieri’s principle for
volume estimation as previously described (Gregersen et al.,
2000; Lambertsen et al., 2009). The rostrocaudal distribution
of the infarct was estimated 3,600 µm anterior of the anterior
commissure to 3,600 µm posterior of the anterior commissure as
previously described (Clausen et al., 2016a; Madsen et al., 2016).
Real-Time Polymerase Chain Reaction
(RT-PCR)
One series of brain tissue was used for RT-PCR. The RNA was
extracted using the TRIzol (Invitrogen) method as previously
described (Meldgaard et al., 2006). Purity of RNA was controlled
spectrophotometrically with 260/280 and 230/260 values using
NanoDrop (Thermo Fisher Scientific). Degradation of RNA was
measured by RNA integrity factor (RIN) using Agilent 2100
Bioanalyzer (Agilent Genomics). Samples were used for PCR
if they had a RIN factor of 7.6 or above. RNA was reverse
transcribed into complementary DNA (cDNA) according to
the High-Capacity cDNA Reverse Transcription kit protocol
(Applied Biosystems). PCR was performed according to the
Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo
Fisher Scientific) protocol. Primer sequences used for RT-PCR
(Table 1) were designed to target exon-exon junctions whenever
possible. Primers were ordered from TAG Copenhagen. Values
were normalized to hypoxanthine phosphoribosyltransferase 1
(HPRT1) mRNA, and relative values were calculated relative to
a calibrator pool of unmanipulated mice as previously described
(Meldgaard et al., 2006).
Cytokine and Receptor Protein
Expression and Drug Concentration
Analysis
One series of brain tissue was lysed in Complete Mesoscale buffer
according to the manufacturer’s protocol (Mesoscale Discovery,
Rockville, MD, United States). Protein concentrations were
determined according to the protocol from Micro BCA protein
TABLE 1 | Primer sequences for RT-PCR.
Gene Primer sequence Product length
CD11b F: 5′ cggaaagtagtgagagaactgtttc 3′ 114 bp
R: 5′ cttataatccaagggatcaccgaattt 3′
CX3CR1 F: 5′ cctgcctctgagaaatggag 3′ 332 bp
R: 5′ atctctccagcccctgaaat 3′
F: 5′ cagcatcgaccggtacctt 3′ 65 bp
R: 5′ gctgcactgtccggttgtt 3′
Arg1 Mm00475988_m1 from Life technologies 65 bp
CCL2 F: 5′ ccccactcacctgctgctac 3′ 86 bp
R: 5′ cctgctgctggtgattctctt 3′
CXCL10 F: 5′ gccgtcattttctgcctcatcct 3′ 113 bp
R: 5′ ctcattctcactggcccgtcatc 3′
CXCL1 F: 5′ catggctgggattcacctcaag 3′ 113 bp
R: 5′ ggcaagcctcgcgaccattct 3′
TREM2 F: 5′ cagccctgtcccaagccctcaac 3′ 134 bp
R: 5′ ctcctcacccagctgccgacacc 3′
P2RY12 F: 5′ tctttgctgggctcatcacgaa 3′ 167 bp
R: 5′ aggcccggctcccagtttag 3′
iNOS F: 5′ ggacagcacagaatgttccagaa 3′ 104 bp
R: 5′ caaaatctctccactgccccag 3′
IL-1β F: 5′ tgtaatgaaagacggcacac 3′ 68 bp
R: 5′ tcttctttgggtattgcttgg 3′
TNFR1 F: 5′ gcccgaagtctactccatcatttg 3′ 91 bp
R: 5′ ggctggggagggggctggagttag 3′
TNFR2 F: 5′ gcccagccaaactccaagcatc 3′ 133 bp
R: 5′ tcctaacatcagcagacccagtg 3′
HPRT1 F′: 5′-aagcagtacagccccaaaatg-3′
R′: 5′-aaatccaacaaagtctggcctgta-3′
F, forward; R, reverse.
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assay kit (Thermo Fischer Scientific). Cytokine and chemokine
concentrations were estimated using an MSD Mouse Pro-
Inflammatory V-Plex Plus Kit (Mesoscale Discovery) and TNF
receptor concentrations using the Mouse TNF-RI and TNFR-
II Ultra-Sensitive Kits (Mesoscale Discovery). XPro1595 levels
were measured in ischemic brain tissue lysates using a human
TNF V-Plex immunoassay (Mesoscale Discovery) as previously
described (Karamita et al., 2017). The standard in the kit was
replaced with XPro1595, which was diluted in the kit diluent
number 2. Etanercept levels were measured using a human
TNFRII Ultra-Sensitive immunoassay (Mesoscale Discovery)
(Karamita et al., 2017). The standard in the kit was replaced with
etanercept diluted in the kit diluent number 2. All kits were read
on a SECTOR Imager 6000 plate reader (Mesoscale Discovery)
according to the manufacturer’s instructions. All samples were
run in duplex, and coefficient of variation (CV) values below
25% were accepted.
Characterization of Cells From Mice With
Genetic Ablation of SolTNF
Cell Purification for Proteomics
Microglia and neurons were purified from cortices from
adult (8 weeks) tmTNF1/1 and tmTNFwt/wt mice by MACS
affinity-based cell sorting (Miltenyi Biotech, Bergisch-Gladbach,
Germany) as previously described (Clausen et al., 2016b). Mice
were sacrificed by cervical dislocation, cortices dissociated with
Neuronal dissociation papain kit (P) (Miltenyi Biotech) and
microglia and neurons purified according to the manufacturer’s
protocol. The cell suspensions were incubated with monoclonal
CD11b beads (Miltenyi Biotech) and applied to LS magnetic
separation columns (Miltenyi Biotech) attached to a magnetic
field for positive selection of microglia. The flow through
was further incubated with Neuron Isolation Kit (Miltenyi
Biotech) and applied to LD magnetic separation columns
(Miltenyi Biotech) for negative selection of neurons. The
cell pellets were stored at −80◦C until preparation for
mass spectrometry.
Sample Preparation/Digestion for Mass Spectrometry
Microglia and neurons were prepared using a filter-aided sample
preparation protein digestion protocol essentially according to
Kruse Meyer et al. (2015). Briefly, samples were lysed in cold
lysis buffer (5% sodium deoxycholate, 50 mM triethylammonium
bicarbonate, pH 8.5) and homogenized by bead beating (Bullet
Blender Gold (NextAdvance, United States); 0.9–2.0 mm steel
bead blend; Setting 10; 2 × 5 min; +4◦C) and heat-denaturized
at 95◦C for 5 min. Protein concentrations were estimated
using a NanoDrop 1000 UV-Vis spectrophotometer (Thermo
Fisher Scientific) using bovine serum albumin as reference
standard. Protein lysate was transferred to a 10 kDa molecular
weight cutoff spin-filter (Millipore, Billerica, MA, United States)
and protein disulfide bonds were reduced with 10 mM
tris(2-carboxyethyl)phosphine (Thermo Fisher Scientific) for
30 min. Afterward, cysteine residues were blocked with 50 mM
chloroacetamide (Sigma-Aldrich, St. Louis, MO, United States)
for 30 min in the dark. Protein digestion was performed with
sequencing grade modified trypsin (Promega, Madison, WI,
United States) at an enzyme to substrate ratio of 1:50 (w/w) for
16 h at 37◦C. The peptide material was eluted from the spin-
filter, acidified with trifluoroacetic acid to a final concentration
of 1% and purified by phase inversions with ethyl acetate 1:2
(v/v). The peptide rich aqueous phase was dried down in a
vacuum centrifuge.
UPLC-MS/MS Sample Analysis
Ultra-performance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS) analysis was performed using
an UltiMate 3000 UPLC system (Thermo Fisher Scientific)
coupled online to a Q Exactive HF mass spectrometer (Thermo
Fisher Scientific). Peptide material was separated on a 75 cm
C18 Acclaim PepMap100 analytical column (Thermo Fisher
Scientific) with 96% solvent A (0.1% FA) and 4% solvent B (0.1%
FA in acetonitrile), which was increased to 30% solvent B on a
60 min ramp gradient at a constant flow rate of 250 nL/min.
Eluting peptides were introduced directly into the mass
spectrometer by a picotip emitter for electrospray ionization
(New Objective, Woburn, MA, United States).
The mass spectrometer was operated in positive mode using
a data-dependent TOP12 acquisition method with the following
settings: mass range m/z 400–1200; isolation window m/z 1.6;
NCE 27; charge state exclusion: unassigned, 1,>6; peptide match
preferred; dynamic exclusion 30 s.
Protein Quantification and Filtering
The .RAW files were investigated by Progenesis QI for
Proteomics to access the chromatographic quality. The raw data
were searched with two complementary label free quantitative
approaches: MaxQuant (v1.5.6.0) against the UniProt Mouse
reference proteome database with isoforms (UP000000589,
November 2016). Standard settings were employed in MaxQuant,
including max two tryptic missed cleavages, and a first search
with 20 ppm mass tolerance followed by data calibration and a
main search with 4.5 ppm mass tolerance. The match between
runs feature was enabled to allow the transfer of identified
precursors between different runs, based on accurate mass and
retention time. The following peptide modifications were found
to be abundant with the applied protocol and were included
in the search: carbamidomethylated cysteine residues (fixed),
acetylation of the N-terminal of proteins (variable), oxidation of
methionine (variable). Identified proteins and peptide spectral
matches were filtered to <1% false discovery rate (FDR)
using a forward/reverse database search strategy in MaxQuant,
and proteins tagged as common contaminants were removed.
Relative protein quantities were calculated by summing the
unique peptide peak areas of each protein in MaxQuant using the
LFQ (label-free quantitation) feature. Additional filtering steps
were employed in Perseus (v1.5.6.0): (1) The quantitation of
any protein was required to be based on at least two unique
peptides. (2) Unique peptides were required to be quantifiable
in at least three of the tmTNFwt/wt or tmTNF1/1 samples.
(3) Pearson’s correlation coefficients (R) between the technical
repeats should be greater than 0.95, based on log2 transformed
protein LFQ values.
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Data Processing
All abundances were log2-transformed and proteins with less
than two unique peptides and (>50% missing values) filtered
out. Proteins with a statistically significant mean abundance
difference between the tmTNFwt/wt and tmTNF1/1 samples
were identified by independent two-sample t-tests in Perseus,
with permutation-based truncation using standard parameters
(s0 = 0.1, 250 randomizations) to correct for multiple
hypothesis testing. In this way, the p-value requirement was
adjusted to expect <5% false positives among the statistically
significant findings.
The MS data has been deposited to the ProteomeXchange
Consortium1 via the PRIDE partner repository with dataset
identifiers PXD014440. Protein-protein interaction analysis was
performed by STRING2.
Phagocytosis Assay
In order to test phagocytic activity of primary microglia derived
from tmTNFwt/wt and tmTNF1/1 mice, the microglia were
plated, activated and incubated with fluorescent beads. As
a measure of phagocytic activity, the number of engulfed
beads was counted and morphological changes estimated as
previously described (Al-Ali et al., 2017; Gao et al., 2017).
Microglial cultures were prepared using brain tissue from
tmTNF1/1 (n = 3) and tmTNFwt/wt (n = 6) pups at post-
natal age 5–7. The meninges and blood vessels were removed,
and brains collected in ice-cold HBSS without Ca2+ and
Mg2+ (Thermo Fisher Scientific) under sterile conditions.
Cortices were processed using Neural Tissue Dissociation
Kit (P) (Miltenyi Biotech) according to the manufacturer’s
protocol. Cell suspensions were filtered through 70 µm cell
strainers (BD Biosciences, San Jose, CA, United States) and
washed with HBSS with Ca2+ and Mg2+ (Thermo Fisher
Scientific). Cell suspensions were centrifuged, and the pellet
used for MACS sorting. Microglia were purified by MACS
sorting using magnetic CD11b+ beads on LS columns (Miltenyi
Biotech) and cultured in culture medium A (76 % Dulbecco’s
modified Eagle’s medium (DMEM) (Thermo Fisher Scientific),
20% FBS (Thermo Fisher Scientific), 1% minimum essential
media (MEM) (Thermo Fisher Scientific), 1% penicillin
streptomycin (Thermo Fisher Scientific), 1% GlutamaxTM
(Gibco, Thermo Fisher Scientific), 1% pyruvate (Thermo
Fisher Scientific)) on poly-L-ornithine-coated plates in a
humified CO2 incubator at 37◦C. After 3 days half of the
media was changed to culture medium B (86% DMEM, 10%
FBS, 1% MEM, 1% penicillin streptomycin, 1% GlutamaxTM,
1% pyruvate). Four days after the media change microglia
were activated by adding 100 ng/mL LPS (Invitrogen, Thermo
Fisher Scientific) for 24 h. After activation, FluoSpheresTM
Carboxylate-Modified Microspheres (1.0 µm, 505/515, yellow-
green fluorescent) (Thermo Fisher Scientific) were added
onto the cultured cells. After 2 h phagocytosis was terminated
by adding cold culture medium B. Cells were fixed with 4%
1http://proteomecentral.proteomexchange.org
2http://string-db.org
paraformaldehyde, blocked in 5% normal goat serum in tris-
buffered saline and incubated overnight in anti-Iba1 antibody
(1:500, Fujifilm Wako Pure Chemical Corporation, Japan).
The next day, cells were stained using alexa 594-conjugated
anti-rabbit antibody (1:750, Alexa594 Molecular Probes)
(Thermo Fisher Scientific) and 4′,6-diamidino-2-phenylindol
(DAPI) (Thermo Fisher Scientific). Pictures were taken using a
FV1000 (Olympus) confocal microscope from nine randomly
chosen positions per coverslip. Analysis of phagocytosis
measured as engulfed beads/cell and cell morphology measured
as cell area, membrane irregularity and perimeter length
was done by automated counting software Puntomorph3
(Al-Ali et al., 2017).
Statistical Analysis
Data are presented as mean ± SEM. Statistical comparison
between the three groups (saline, Xpro1595, and etanercept)
was assessed by one-way ANOVA followed by Tukey’s
post hoc test (GraphPad Prism Software Inc., San Diego,
CA, United States). Comparison of the rostrocaudal distribution
of the infarct and comparison of phagocytosis in tmTNF1/1
and tmTNFwt/wt microglia were tested by two-way ANOVA
followed by Tukey’s post hoc test. Statistical significance of
the asymmetry of the paws in the grip strength test and the
Hargreaves nociception test was tested by Student’s paired
t-test. Normal distribution of variables was tested using
both Brown-Forsythe and Bartlett’s tests. Significance was set
at p ≤ 0.05.
RESULTS
Topical Delivery of XPro1595 Decreases
Infarct Volume 1 and 3 Days After
pMCAO
Infarct volumes were estimated in Toluidine blue-stained
brain sections from mice treated topically or i.c.v. with
saline, XPro1595, or etanercept and allowed to survive 1
or 3 days after pMCAO (Figure 1 and Supplementary
Figure 1A). At day 1, infarct volumes were significantly
reduced in mice treated topically with XPro1595 compared
to mice treated topically with saline (Figure 1B). Etanercept
treatment showed no effect. The rostrocaudal distribution of
the infarcts was comparable between groups (Figure 1C).
At day 3, infarct volumes were also significantly reduced in
mice treated topically with XPro1595 (Figure 1E). Again, the
rostrocaudal distribution of the infarct was comparable between
groups (Figure 1F).
Intracerebroventricular administration of XPro1595
or etanercept was not effective in decreasing infarct size
(Supplementary Figure 1A). In support of this, we observed no
difference in functional outcomes as assessed by the Hargreaves
thermal hyperalgesia (Supplementary Figure 1B) or grip
strength tests (Supplementary Figures 1C,D), except for a total
3https://github.com/HA-Lab/PuntoMorph
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FIGURE 1 | Infarct volume and rostrocaudal distribution after topical administration of TNF inhibitors. (A) Toluidine blue-stained brain sections of mice treated
topically with saline, XPro1595, or etanercept and allowed to survive 1 day after pMCAO. Scalebar 500 µm. (B) Infarct volume estimation 1 day after pMCAO.
N(saline) = 11; n(XPro1595) = 6; n(etanercept) = 4. (C) Rostrocaudal distribution of the infarct 1 day after pMCAO. (D) Toluidine blue-stained brain sections of mice
treated topically with saline, XPro1595, or etanercept and allowed to survive 3 days after pMCAO. (E) Infarct volume estimation 3 days after pMCAO. N(saline) = 12;
n(XPro1595) = 15; n(etanercept) = 17. (F) Rostrocaudal distribution of the infarct 3 days after pMCAO. ∗p ≤ 0.05, one-way ANOVA followed by Tukey’s post hoc test.
FIGURE 2 | Detection of TNF inhibitors in ischemic brain tissue 24 h after pMCAO. (A) Concentration of XPro1595 in brain tissue after topical and i.c.v.
administration. N = 4–7/group (excluded due to too high CV values: saline pump, n = 4; saline i.c.v., n = 2). (B) Concentration of etanercept in brain tissue after
topical and i.c.v. administration. N = 2–6/group (excluded due to too high CV values: saline i.c.v., n = 2; XPro1595 i.c.v., n = 1).
weaker grip strength on day 3 compared to baseline in mice
treated with etanercept (Supplementary Figure 1D).
XPro1595 and Etanercept Can Be
Detected in Brain Ischemic Tissue
To validate the presence of XPro1595 and etanercept and estimate
their concentrations in the ischemic brain following topical
and i.c.v. delivery, we measured the concentration of XPro1595
and etanercept 1 day after pMCAO (Figures 2A,B). We found
topical administration to be an efficient method to deliver a high
concentration of XPro1595 to neural tissue (Figure 2A). After
topical administration, the concentration of XPro1595 in brain
tissue 1 day after pMCAO was 630,300 ± 160,000 pg/mg. The
concentration of XPro1595 was lower after i.c.v. administration,
with a mean of 69,400 ± 51,300 pg/mg (Figure 2A). This
concentration in the neural tissue is, however, sufficient to
neutralize solTNF and to promote neuroprotection, based on
previous publications in an animal model of Alzheimer’s disease
(MacPherson et al., 2017).
Etanercept was detected in the brain tissue after both
delivery routes (Figure 2B). The concentration of etanercept
in brain tissue 1 day after pMCAO was 1,600 pg/mg after
topical administration and 1,500 ± 200 pg/mg after i.c.v.
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FIGURE 3 | Flow cytometric analysis of ipsilateral hemispheres in sham and pMCAO mice after topical saline, XPro1595, or etanercept treatment. (A) Gating
strategy for CD45+ cells, CD45dimCD11b+ microglia, CD45highCD11b+ leukocytes, CD45highCD11b+Ly6C+Ly6G- macrophages, and
CD45highCD11b+Ly6C+Ly6G+ granulocytes. (B–D) Changes in CD45dimCD11b+ microglia presented as % of CD45+ cells 3 days after sham surgery or 1 or 3
days after pMCAO. (E–G) Changes in CD45highCD11b+Ly6C+Ly6G- macrophages presented as % of CD45+ cells after sham surgery or 1 or 3 days after pMCAO.
(H–J) Changes in CD45highCD11b+Ly6C+Ly6G+ granulocytes presented as % of CD45+ cells after sham surgery or 1 or 3 days after pMCAO. (K–M) Changes in
CD3+ T cells presented as % of CD45+ cells after sham surgery or 1 or 3 days after pMCAO. N(sham) = 3–5/group; n(day 1) = 4–5/group; n(day 3) = 5/group;
∗p ≤ 0.05; one-way ANOVA followed by Tukey’s post hoc test.
administration. This demonstrated that both XPro1595 and
etanercept successfully accessed the ischemic brain tissue.
Topical Treatment With XPro1595 Does
Not Affect Microglial and Leukocyte Cell
Populations After pMCAO
To investigate potential changes in microglial and
leukocyte populations in mice subjected to pMCAO and
treated topically with saline, XPro1595 or etanercept, we
performed flow cytometry and gated for CD45dimCD11b+
microglia, CD45dimCD11b+Ly6C+Ly6G− macrophages,
CD45dimCD11b+Ly6C+Ly6G+ granulocytes (Figure 3A), and
CD45+CD3+ T cells.
We found that compared to saline, both Xpro1595 and
etanercept treatment increased the percentage of microglia in
the ipsilateral cortex 3 days after sham surgery (Figure 3B),
whereas no difference was observed between groups at day
1 (Figure 3C) or day 3 (Figure 3D) after pMCAO. In all
groups of mice 3 days after pMCAO, the microglial population
constituted ∼80% of all live CD45+ cells in the contralateral
cortex, with only ∼60% in sham. By 1 day after pMCAO the
microglial population constituted ∼60% of all live CD45+ cells
(Supplementary Figures 2A–C). The percentage of infiltrating
macrophages (Figures 3E–G), granulocytes (Figures 3H–J),
and T cells (Figures 3K–M) did not differ between groups at
any time point investigated, although the percentages of cells
increased over time in the ipsilateral cortex (Figures 3E–M)
and remained relatively constant in the contralateral cortex
(Supplementary Figures 2D–L).
Since microglia and macrophages upregulate their expression
of CD11b and CD45 after ischemia (Ito et al., 2001; Ponomarev
et al., 2005; Clausen et al., 2008; Morrison and Filosa, 2013),
their activation status was evaluated based on the MFI of
these cell surface markers. MFIs of CD11b and CD45 were
comparable between treatment groups 3 days after sham surgery
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and 1 and 3 days after pMCAO (Supplementary Figures 3A–L).
However, both microglia and leukocytes seemed to downregulate
their expression of CD11b and upregulate their expression of
CD45 3 days after pMCAO, which was not the case in sham
mice and 1 day after pMCAO (Supplementary Figures 3A–L,
please compare C to A and B; I to G and H; F to D and E;
and L to J and K).
XPro1595 Affects Microglial Activation
We next investigated changes in mRNA expression of selected
microglial/macrophage and inflammatory markers in brain
tissue derived from mice subjected to pMCAO and treated
topically (Figure 4) or i.c.v. (Supplementary Figure 4) with
saline, XPro1595, or etanercept and allowed to survive 1 or 3
days after pMCAO.
We found Tnf mRNA expression to be significantly
upregulated 1 and 3 days after pMCAO in mice treated topically
with XPro1595 when compared to saline- and etanercept-treated
mice (Figure 4A). Tnfrsf1a (TNFR1, Figure 4B) and Tnfrsf1b
(TNFR2, Figure 4C) mRNA expression was comparable between
treatment groups at both days 1 and 3 after pMCAO. At 3 days, Il-
1beta mRNA levels were significantly upregulated in mice treated
topically with XPro1595 compared to saline- and etanercept-
treated mice (Figure 4D), whereas no significant changes in
Nos2 (iNOS) mRNA expression was observed between groups,
although XPro1595 tended to downregulate the expression at 3
days (p = 0.08; Figure 4E).
To study whether TNF inhibition using XPro1595 or
etanercept affects chemokine gene expression, we measured the
mRNA levels of Cxcl1, Cxcl10, and Ccl2 at 1 and 3 days after
pMCAO. Topical etanercept treatment significantly increased
Cxcl1 mRNA compared to saline and XPro1595 at day 1 and
compared to XPro1595 at day 3 after pMCAO (Figure 4F). In
contrast, Cxcl10 mRNA levels decreased at day 3 in mice treated
topically with etanercept compared to saline (Figure 4G), and
Ccl2 mRNA levels significantly increased at day 3 in XPro1595-
treated mice compared to both saline- and etanercept-treated
mice (Figure 4H).
We further measured mRNA expression levels of
microglial/macrophage markers Cx3cr1, P2ry12, Trem2,
Cd11b, and Arg1. We found that at days 1 and 3 after pMCAO,
topical XPro1595 treatment decreased Cx3cr1 mRNA expression
compared to saline-treated mice (Figure 4I). In contrast, P2ry12
mRNA expression was significantly increased at 1 day after
pMCAO in topically XPro1595-treated mice compared to saline-
treated mice (Figure 4J), as well as Trem2 mRNA expression at
1 and 3 days after pMCAO (Figure 4K). Cd11b and Arg1 mRNA
levels were comparable between groups except for a significant
decrease in Arg1 mRNA levels in XPro1595-treated mice at day 3
(Figures 4L,M).
Even though i.c.v. administration of TNF inhibitors had
no effect on infarct volume or functional outcome, we also
investigated potential changes in mRNA expression after i.c.v.
injection of XPro1595 or etanercept (Supplementary Figure 4).
We observed no change in Tnf, Tnfrsf1a, Tnfrsf1b, Il-1beta, Nos2,
Cxcl1, Cx3cr1, or CD11b mRNA expression between groups.
Etanercept significantly increased Cxcl10 mRNA levels compared
to saline at day 1 and compared to both XPro1595 and saline
3 days after pMCAO (Supplementary Figure 4). Also, P2ry12
mRNA levels increased significantly at day 1 in etanercept-treated
mice compared to saline- and Xpro1595-treated mice, and Ccl2
and Trem2 mRNA levels increased significantly at day 3, while
Arg1 decreased significantly.
Cytokine, Chemokine, and TNF Receptor
Expression in Brain Tissue 1 and 3 Days
After TNF Inhibitor Treatment
To study whether topical (Figure 5) or i.c.v. (Supplementary
Figure 5) XPro1595 and etanercept treatment after pMCAO
affected cytokines, TNF receptor and/or chemokine protein
levels, we measured TNF, TNFR1, TNFR2, IL-1β, CXCL1, IL-
6, IL-10, IL-4, IL-5, and IL-12p70 levels in brain tissue 1 day
after pMCAO, when neuroinflammation is maximal (Lambertsen
et al., 2012), in addition to 3 days after pMCAO using
multiplex ELISA.
We found that despite increased Tnf mRNA expression after
topical XPro1595 treatment, the protein expression tended to be
downregulated in XPro1595-treated mice (p = 0.06, Figure 5A),
whereas TNF levels in etanercept-treated mice were comparable
to saline-treated mice 1 day after pMCAO. At 3 days, TNF levels
had increased significantly in etanercept-treated mice compared
to saline-treated mice. Compared to topical saline treatment,
etanercept treatment downregulated TNFR1 levels at day 1,
which also showed tendency to be downregulated after XPro1595
treatment (p = 0.08), whereas TNFR1 levels were comparable
at 3 days (Figure 5B). Topical treatment had no effect on
expression of TNFR2, IL-1β, Cxcl1, IL-6, IL-10, IL-4, IL-5, or
IL-12p70 (Figures 5C–J).
Intracerebroventricular administration of TNF inhibitors
showed no effect on the TNF or TNFR1 protein expression
(Supplementary Figures 5A,B) although TNFR2 was
downregulated after etanercept-treatment compared to
saline treatment 1 day after pMCAO (Supplementary
Figure 5C). Treatment with XPro1595 showed a tendency
toward reducing TNFR2 levels at day 1 after pMCAO (p = 0.07)
(Supplementary Figure 5C). At 1 day after pMCAO, etanercept
treatment significantly increased IL-1β levels compared
to saline (Supplementary Figure 5D), but no effect was
observed on CXCL1, IL-6, IL-10, IL-4, IL-5, or IL-12p70 levels
(Supplementary Figures 5E–J).
tmTNF Microglia Have an Upregulated
Expression of Phagocytosis-Related
Proteins
In order to investigate the hypothesis that ablation of solTNF
improves microglial phagocytosis, we investigated differentially
expressed proteins in microglia derived from tmTNF1/1 and
tmTNFwt/wt mice using mass spectrometry. In total, 1,564
proteins with two or more unique peptides were quantified
by label free quantification in microglia cells (Supplementary
Table 1). Of these, 87 proteins were differentially regulated
between tmTNFwt/wt and tmTNF1/1 mice (Figure 6A).
Several of the upregulated proteins, 3-mercaptopyruvate
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FIGURE 4 | Inflammatory gene profile 1 and 3 days after pMCAO in mice treated topically with saline, XPro1595, or etanercept. mRNA expression of cytokines,
pro-inflammatory molecules, chemokines, and microglial markers presented as % of gene expression in saline-treated animals (A–M). (A) Expression of Tnf mRNA.
(B) Expression of Tnfrsf1a (TNFR1) mRNA. (C) Expression of Tnfrsf1b (TNFR2) mRNA. (D) Expression of Il1β mRNA. (E) Expression of Nos2 (iNOS) mRNA.
(F) Expression of Cxcl1 mRNA. (G) Expression of Cxcl10 mRNA. (H) Expression of Ccl2 mRNA. (I) Expression of Cx3cr1 mRNA. (J) Expression of P2ry12 mRNA.
(K) Expression of Trem2 mRNA. (L) Expression of CD11b mRNA. (M) Expression of Arg1 mRNA. N(day 1) = 4–11/group, n(day 3) = 5–6/group; ∗p ≤ 0.05,
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, ∗∗∗∗p ≤ 0.0001; one-way ANOVA followed by Tukey’s post hoc test.
sulfurtransferase (3-MPST), hematopoietic prostaglandin D
synthase (HPGDS) and apoptosis-associated speck-like protein
containing a CARD (PYCARD/ASC) are neuroprotective
(Liu et al., 2009; Chen et al., 2015; Kimura et al., 2017;
Shan et al., 2017) or related to regulation of phagocytosis
(Rajakariar et al., 2007; Ippagunta et al., 2011). 3-MPST has
previously been shown to be upregulated in activated microglia
treated with a neuroprotective compound (Cobourne-Duval
et al., 2018). tmTNF expressing microglia had an increased
expression of HPGDS, which is known to be expressed in
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FIGURE 5 | Cytokine and TNF receptor protein expression in brain tissue 1 and 3 days after pMCAO in mice treated topically with saline, XPro1595, or etanercept.
(A) Expression of TNF (n = 4–11/group). (B) Expression of TNFR1 (n = 4–11/group). (C) Expression of TNFR2 (n = 4–10/group). (D) Expression of IL-1β
(n = 3–11/group). (E) Expression of CXCL1 (n = 3–11/group). (F) Expression of IL-6 (n = 3–9/group). (G) Expression of IL-10 (n = 3–10/group). (H) Expression of IL-4
(n = 2–11/group). (I) Expression of IL-5 (n = 4–10/group). (J) Expression of IL-12p70 (n = 4–11/group). ∗∗p ≤ 0.01; one-way ANOVA with Tukey’s post hoc test.
activated microglia in the core of the infarct after ischemic
stroke and to enhance their differentiation into a phagocytic
phenotype (Mohri et al., 2003; Liu et al., 2007). PYCARD/ASC
supports the function of a normal immune system (Ippagunta
et al., 2011). Among the downregulated proteins was MPO.
Interestingly, upregulation of myeloperoxidase (MPO)
expression is linked to pathological phagocytosis of myelin
leading to demyelination in patients with multiple sclerosis
(Minohara et al., 2006; Gray et al., 2008). Moreover, the
expression of Methyl-CpG-binding protein 2 (MECP2) (Cronk
et al., 2015) was downregulated in tmTNF expressing microglia.
The absence of microglial MECP2 has shown to increase
Tnf mRNA expression (Cronk et al., 2015). Interestingly,
tmTNF expressing microglia had downregulated expression
of Histone H1.5, which promotes microglial proinflammatory
functions (Gilthorpe et al., 2013), Heat shock protein 27,
which is neuroprotective in ischemic brain (Stetler et al.,
2012) and Heat shock 70 kDa protein 1, which functions
as a chaperone (Stetler et al., 2010) supporting earlier
studies showing solTNF to be needed for optimal control
of inflammatory response (Ruuls et al., 2001; Musicki et al., 2006;
Dambuza et al., 2011; DeBerge et al., 2014). Downregulation
of Human growth and transformation-dependent protein
(HGTD-P), a protein which is proapoptotic in ischemia
(Qu et al., 2009), and downregulation of Vimentin, which
has been shown to mediate microglial activation (Jiang
et al., 2012), supports the beneficial function of tmTNF.
Two other histones, Histone H4 and Core histone macro-
H2A.1 were downregulated in tmTNF expressing microglia.
String analysis of the differentially regulated proteins in
microglia showed clustering of the aforementioned immune
system-related proteins Histone H1.5, Heat shock protein 27,
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FIGURE 6 | Proteome analysis of primary microglia from tmTNFwt/wt and tmTNF1/1 mice. (A) Differentially expressed proteins in tmTNFwt/wt and tmTNF1/1
microglia (n = 4/group). (B) String analysis of differentially expressed proteins in tmTNFwt/wt and tmTNF1/1 microglia. Red circle, FCERI-mediated NF-kappa B
activation; blue circle, ribosomal proteins; green circle, neutrophil degranulation; turquoise circles, proteins related to phagocytosis.
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FIGURE 7 | Microglia from tmTNF1/1 mice have increased phagocytic
activity after LPS activation. (A) Primary microglia cultures stained for Iba1
(red) and DAPI (blue) demonstrating phagocytosis of FluoSpheres
Carboxylate-Modified Microspheres (green). Staining of tmTNFwt/wt microglia
(upper left), tmTNFwt/wt + LPS (upper right), tmTNF1/1 (lower left), tmTNF1/1
+ LPS (lower right). Scalebar = 100µm. (B) Engulfed beads/cell in tmTNFwt/wt
and tmTNF1/1 microglia. N(tmTNFwt/wt) = 426 cells/25 FOV, n(tmTNFwt/wt +
LPS) = 282 cells/17 FOV, n(tmTNF1/1) = 169 cells/20 FOV, n(tmTNF1/1 +
LPS) = 137 cells/20 FOV. [Two-way ANOVA: treatment ∗∗∗p < 0.001, F(1,
78) = 6.03; genotype ∗p < 0.05, F(1, 78) = 210.1; interaction ∗∗p < 0.01 F(1,
78) = 8.05]. (C–E) Morphological features of microglia before and after LPS
activation. (C) Area. [Two-way ANOVA: treatment ∗∗∗p < 0.001, F(1,
78) = 373.3]. (D) Perimeter. [Two-way ANOVA: treatment ∗∗∗p < 0.001, F(1,
78) = 96.08]. (E) Ruffling. [Two-way ANOVA: treatment ∗∗∗p < 0.001, F(1,
78) = 132.5]. For C-E, N(tmTNFwt/wt) = 426 cells/25 FOV, n(tmTNFwt/wt +
LPS) = 282 cells/17 FOV, n(tmTNF1/1) = 169 cells/20 FOV, n(tmTNF1/1 +
LPS) = 137 cells/20 FOV. LPS, lipopolysaccharide; FOV, field of view.
Methyl-CpG-binding protein 2, Heat shock 70 kDa protein,
Core histone macro-H2A.1, Vimentin, HPGDS, and Histone
H4 (Figure 6B).
Microglia Expressing Only tmTNF
Display Improved Phagocytic Properties
Due to the upregulated expression of phagocytosis-related
proteins in microglia expressing only tmTNF, we next
investigated the phagocytic properties and morphological
changes 1 day after LPS stimulation in primary microglia
derived from 5 to 7 days old tmTNF1/1 and tmTNFwt/wt pups
(Figure 7A). Phagocytosing microglia have a neuroprotective
role in clearing apoptotic cells and debris after stroke (Neumann
et al., 2009; Sierra et al., 2013). At 1 day after LPS stimulation,
the phagocytic activity of microglia derived from tmTNF1/1
pups was significantly increased compared to microglia derived
from tmTNFwt/wt pups, measured as engulfed beads per cell
(Figure 7B). Cell area (Figure 7C), perimeter length (Figure 7D),
and membrane irregularity (Figure 7E) increased significantly
after LPS activation in both tmTNFwt/wt and tmTNF1/1
microglia indicating both tmTNFwt/wt and tmTNF1/1 microglia
to take an amoeboid form after LPS activation. Cell morphology
was, however, comparable between tmTNFwt/wt and tmTNF1/1
microglia after LPS activation (Figures 7A,C–E).
Proteomic Characterization of Neurons
Derived From tmTNF1/1 and tmTNFwt/wt
Mice
In total, 763 proteins with two or more unique peptides were
quantified by label free quantification in neurons. Of them, 11
proteins were differentially expressed between tmTNF1/1 and
tmTNFwt/wt mice (Supplementary Figure 6). Calcium-activated
potassium channel subunit alpha-1 (KCa1.1) was upregulated in
tmTNF1/1 mice. HGTD-P that promotes apoptosis in ischemia
(Qu et al., 2009) was downregulated in neurons derived from
tmTNF1/1 mice suggesting improved neuroprotection.
DISCUSSION
In the present study, we found that topical administration of the
selective solTNF inhibitor XPro1595 decreased infarct volumes
1 and 3 days after pMCAO. Inhibition of TNF by the non-
selective solTNF and tmTNF inhibitor etanercept showed no
effect. Furthermore, there was no reduction in infarct volume or
improvement in functional outcome when TNF inhibitors were
delivered by i.c.v. administration, even though the concentrations
of the inhibitors in brain tissue were sufficient to neutralize
TNF and potentially promote neuroprotection as demonstrated
in previous studies using animal models of Alzheimer’s disease
(MacPherson et al., 2017).
We have previously shown that topical, but not systemic,
administration of XPro1595 decreased lesion volume and
improved functional outcome after moderate spinal cord injury
(Novrup et al., 2014). Systemic administration of XPro1595 and
etanercept had no effect on the infarct volume after pMCAO
(Clausen et al., 2014), and systemic etanercept administration
had no effect after transient focal cerebral ischemia (Sumbria
et al., 2012), indicating that TNF inhibitors have to be
administered directly to infarcted brain tissue and not by
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intracerebroventricular or peripheral routes. The length of
treatment may also play a role in suppressing the infarct
formation in the acute phase of ischemic stroke. It is known
that the infarct volume correlates with functional outcome (Saver
et al., 1999; Yoo et al., 2012), and since TNF inhibitors are
known to improve functional outcome even without reduction
in infarct volume when administered systemically (Clausen
et al., 2014), assessment of the functional outcome would have
been ideal to evaluate the neuroprotective effects of topical
XPro1595 administration. Evaluation of the functional outcome
was impossible, however, due to the placement of the mini-
osmotic pumps in topically treated animals.
The expression of Tnf mRNA in central nervous system has
been shown to peak 12 h after pMCAO in mice (Lambertsen
et al., 2005, 2009), and TNF protein expression 24 h after pMCAO
(Lambertsen et al., 2005, 2009; Clausen et al., 2008). Expression
of Tnf mRNA in the contralateral hemisphere has been shown
to remain at baseline levels after pMCAO (Lambertsen et al.,
2009). In permanent focal cerebral ischemia, TNF is believed to
exert its neuroprotective effects through TNFR1 (Taoufik et al.,
2007; Lambertsen et al., 2009). Tnfr1 mRNA expression peaks 1–
2 days after pMCAO (Lambertsen et al., 2007, 2009), while the
protein expression can be detected from 4 to 6 h until 5 days
(Botchkina et al., 1997; Lambertsen et al., 2007). The expression
of Tnfr2 increases 1–10 days after pMCAO and reaches its
peak 5 days after occlusion (Lambertsen et al., 2007). The
protein expression of TNFR2 can be detected 24 h after pMCAO
(Botchkina et al., 1997). In our study, topical administration of
XPro1595 tended to suppress the expression of TNF protein
1 day after pMCAO, while gene expression was significantly
upregulated due to the feedback mechanism by which TNF
induces its own gene expression when the amount of available
protein is repressed. In addition, inhibition of both solTNF and
tmTNF with etanercept downregulated TNFR1 protein levels at
day 1. Together with earlier findings that TNFR1 knock-out
mice develop larger infarct volumes (Bruce et al., 1996; Gary
et al., 1998) and neuroprotection in ischemic stroke is mediated
through the TNFR1-NFκB-FLIP(L)-ERK1/2 pathway (Taoufik
et al., 2007; Lambertsen et al., 2009; Marques-Fernandez et al.,
2013), downregulation of TNFR1 is likely to contribute to the lack
of neuroprotection after TNF inhibition with etanercept (Gary
et al., 1998; Lambertsen et al., 2009). Given the neuroprotective
effect of TNFR2 signaling in our spinal cord injury model
(Novrup et al., 2014) and the protective effect of this receptor
in chronic, inflammatory conditions such as multiple sclerosis
(Brambilla et al., 2011; Gao et al., 2017), we cannot exclude
that TNFR2 signaling on microglia may have contributed to the
protective effects observed after topical XPro1595 treatment.
TNF is primarily secreted by activated resident microglia
and at later time points by infiltrating macrophages after
pMCAO (Clausen et al., 2008; Lambertsen et al., 2009). In
contrast to earlier studies showing that systemic inhibition of
solTNF increased the number of microglia 6 and 24 h after
pMCAO (Clausen et al., 2014), flow cytometric analysis of the
percentage of microglia and infiltrating macrophages or their
CD11b and CD45 MFI values showed no difference between
treatment groups. Interestingly, the number of CD45dimCD11b+
microglia was higher in sham mice treated with either TNF
inhibitor when compared to saline-treated mice. In contrast
to earlier studies where XPro1595 decreased glial activation in
an animal model of Parkinson’s disease (Barnum et al., 2014),
it is possible that topical administration of XPro1595 shifted
the microglial phenotype without influencing the activation
status of the cells. In support of this, Cx3cr1 mRNA levels
were significantly downregulated after 1 and 3 days of topical
administration of XPro1595. Also, CX3CR1 deficiency has been
shown to be neuroprotective in the early phase after ischemia by
promoting microglial polarization to an M2-like phenotype and
to decrease microglial activation and neurotoxicity by decreasing
the expression of M1-like microglial phenotype that is associated
with proinflammatory molecules; all of which lead to smaller
infarct volumes (Fumagalli et al., 2013; Tang et al., 2014).
XPro1595 also increased the expression of P2ry12, a protein
related to resting state microglia (Haynes et al., 2006), 1 day after
pMCAO when administered topically, suggesting that XPro1595
decreases microglial activation as earlier reported (Barnum et al.,
2014; Hsiao et al., 2014; Novrup et al., 2014; MacPherson et al.,
2017). Furthermore, the expression of Trem2 was upregulated 1
and 3 days after pMCAO in mice treated topically with XPro1595.
Trem2-knock out mice have altered microglial phagocytosis and
larger infarct volumes after cerebral ischemia (Takahashi et al.,
2005; Kawabori et al., 2015), supporting earlier studies where
XPro1595 was found to promote neuroprotection by improving
phagocytosis of dying neurons and cell debris in demyelinated
lesions in an animal model of multiple sclerosis (Karamita et al.,
2017). Chemokine expression was also altered after treatment
with TNF inhibitors.
In the present study, topical administration of XPro1595
increased the relative expression of Ccl2 mRNA 3 days after
pMCAO. CCL2 is necessary for hypoxia-required ischemic
tolerance, and upregulation after XPro1595 treatment supports
the neuroprotective properties of the selective solTNF inhibitor
(Stowe et al., 2012; Wacker et al., 2012). Cxcl1 mRNA, a
proinflammatory granulocyte attracting chemokine expressed by
monocytes and granulocytes, was upregulated in etanercept-
treated but not XPro1595-treated mice 1 and 3 days after
pMCAO. However, there was no difference in the CXCL1
protein levels or in granulocyte infiltration between the treatment
groups, contradicting earlier findings where systemic treatment
with TNF inhibitors decreased the number of infiltrating
granulocytes (Clausen et al., 2014) and TNF deficiency increased
the number of infiltrating leukocytes 24 h after pMCAO
(Lambertsen et al., 2009).
Intracerebroventricular administration of XPro1595 or
etanercept had no effect on the infarct volume nor any
beneficial effect on functional outcome despite both drugs
being shown to access neural tissue in therapeutically relevant
concentrations. In both experimental conditions (i.c.v. versus
topical administration), XPro1595 and etanercept were present in
more than 1000-fold excess of TNF in the ischemic brain tissue.
However, it is possible that despite the penetration of XPro1595
and etanercept, the drugs did not reach their site of action,
the penumbra, within the therapeutic window, which in our
pMCAO model has been shown to be 6 h (Clausen et al., 2006).
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Proteomic characterization of microglia derived from
tmTNF1/1 mice revealed that several phagocytosis-related
proteins were significantly upregulated compared to proteins
from microglia derived from tmTNFwt/wt mice. Microglia derived
from tmTNF1/1 mice showed an upregulated expression of
3-MPST, an enzyme protecting cells from oxidative stress by
producing redox regulators (Kimura et al., 2017). In addition,
3-MPST regulates hydrogen sulfide production, which has been
shown to promote phagocytosis (Dufton et al., 2012), functions
as a vasodilator supporting blood flow (Zhao et al., 2001), and
promotes angiogenesis (Papapetropoulos et al., 2009). Among
the upregulated proteins was HPGDS, which is upregulated in
microglia and macrophages after ischemic stroke and is likely to
promote microglia/macrophage differentiation to the phagocytic
phenotype (Mohri et al., 2003, 2006; Liu et al., 2007). In addition,
HPGDS inhibits production of reactive oxygen species and
downregulates the expression of the pro-inflammatory cytokine
IL-1β through the formation of prostaglandins (Gomez-Abellan
et al., 2015). Microglia derived from tmTNF1/1 mice also had
an upregulated expression of PYCARD/ASC. PYCARD/ASC
deficient mice have impaired lymphocyte migration and are
deficient in the number of lymphocytes and dendritic cells in
secondary lymphoid organs compromising the normal immune
system function (Ippagunta et al., 2011). Upregulation of the
microglial PYCARD/ASC could contribute to the maintenance
of the innate immune system and the secondary lymphoid
organs where tmTNF has shown to be crucial (Ruuls et al., 2001;
Alexopoulou et al., 2006). Among the downregulated proteins in
tmTNF expressing microglia was MPO, a reactive oxygen species
generating enzyme known to be expressed by leukocytes and to
increase in cerebral ischemia (Lau and Baldus, 2006; Breckwoldt
et al., 2008). Inhibition of MPO increases the proliferation and
survival of neurons in animal models of ischemic stroke (Kim
et al., 2016). In addition, HGTD-P, that mediates apoptosis in the
ischemic brain when activated by hypoxia-inducible factor-1 (Qu
et al., 2009), was downregulated in tmTNF expressing microglia.
In order to study whether the up- and downregulation
of the phagocytosis-related proteins would affect microglial
phagocytosis in vitro, we tested phagocytic capacity after 1 day
of LPS stimulation. Primary microglia derived from tmTNF1/1
mice showed increased phagocytic activity that most likely
can lead to increased clearing of debris thereby promoting
neuronal survival in the ischemic area when solTNF is ablated.
Earlier studies have demonstrated increased phagocytosis after
inhibition of solTNF (Karakantza et al., 2003) and impaired
phagocytic ability of TNFR2 deficient microglia (Gao et al., 2017).
Since tmTNF preferentially binds to TNFR2, it is likely that
phagocytosis is regulated through the tmTNF-TNFR2 pathway.
In the present study, we also show that inhibition of solTNF by
XPro1595 increased the gene expression of Trem2, a receptor that
is known to be involved in promoting microglial phagocytosis
(Takahashi et al., 2005), an upregulation that was likely to increase
microglial phagocytosis in mice treated topically with XPro1595.
This study demonstrates that selective inhibition of solTNF is
neuroprotective after pMCAO when administered topically for 1
and 3 consecutive days. Furthermore, topical administration of
XPro1595 promotes a phagocytic, microglial phenotype possibly
supporting a neurotrophic environment in the ischemic lesion.
We suggest that topical administration of XPro1595 has potential
to be clinically beneficial in treating patients with ischemic stroke.
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